rs6020611 — PTPN1

PTP1B's Genetic Shadow — The Intronic PTPN1 Tag SNP rs6020611

Protein tyrosine phosphatase 1B (PTP1B), encoded by the PTPN1 gene on chromosome 20q13, is one of the most rigorously validated drug targets in metabolic medicine. Its job is to put the brakes on insulin signaling: once insulin binds its receptor and activates a phosphorylation cascade, PTP1B dephosphorylates the activated insulin receptor¹¹ dephosphorylates the activated insulin receptor
removes phosphate groups from key tyrosine residues on the insulin receptor, switching off downstream glucose uptake signals and its substrates, terminating the signal. In lean tissues, this dampening is normal and necessary. In people with elevated PTP1B activity or expression, however, insulin signaling is chronically suppressed — a molecular origin of insulin resistance that precedes clinical type 2 diabetes by years or decades.

rs6020611 sits deep within intron 7 of PTPN1, at GRCh38 position chr20:50,578,070. It does not alter any amino acid. Its clinical importance comes from its position inside a ~100-kb linkage disequilibrium block²² ~100-kb linkage disequilibrium block
A genomic stretch where nearby variants are inherited together as a unit because recombination between them is very rare, so one SNP can tag the metabolic effects of the entire block that encompasses the full PTPN1 gene — the same block where the most-studied PTPN1 risk haplotypes reside. rs6020611 therefore functions as a tag SNP: its alleles act as a proxy readout for the haplotype pattern across this entire regulatory region.

The Mechanism

The functional driver within the PTPN1 LD block is likely a non-coding variant in a promoter or enhancer element rather than any single missense change. Research has confirmed that risk-associated PTPN1 haplotypes increase PTP1B mRNA expression in skeletal muscle — more PTP1B protein means more aggressive dephosphorylation of the insulin receptor, weaker insulin signaling, and reduced glucose uptake per unit of circulating insulin. The lipid associations of rs6020611 may reflect this same mechanism acting in the liver, where PTP1B regulates insulin-dependent suppression of VLDL assembly and LDL receptor expression. When insulin signaling in hepatocytes is blunted, LDL receptor recycling slows and plasma LDL rises — a mechanism connecting insulin resistance to atherogenic lipid profiles independent of body weight.

The Evidence

The most direct evidence for rs6020611 comes from Bauer et al. 2010³³ Bauer et al. 2010
Bauer F et al. PTPN1 polymorphisms are associated with total and low-density lipoprotein cholesterol. Eur J Cardiovasc Prev Rehabil. 2010 Feb;17(1):28-34, who genotyped four PTPN1 tag SNPs in 382 Dutch Caucasian men aged 40–80. The minor (A) alleles of rs6020611, rs6067484, and rs1060402 were each associated with higher total plasma cholesterol and LDL (P<0.05), specifically in men with BMI below 26 kg/m². Haplotypes combining these minor alleles showed borderline significance for the same lipid phenotypes. The BMI-stratified finding suggests that PTP1B-driven insulin resistance elevates cholesterol through a direct hepatic lipid mechanism, but is masked in overweight individuals where adiposity-driven insulin resistance dominates the signal.

The broader PTPN1 LD block is well-replicated for insulin resistance and T2D. Bento et al. 2004⁴⁴ Bento et al. 2004
Bento JL et al. Association of protein tyrosine phosphatase 1B gene polymorphisms with type 2 diabetes. Diabetes. 2004 Nov;53(11):3007-12 studied 23 noncoding SNPs across 161 kb and found haplotypes with OR ~1.3 for T2D in Caucasians, with a population-attributable risk of 17–20%. Palmer et al. 2004⁵⁵ Palmer et al. 2004
Palmer ND et al. Association of PTPN1 gene polymorphisms with measures of glucose homeostasis in Hispanic Americans. Diabetes. 2004 Nov;53(11):3013-9 showed in 811 Hispanic subjects that 20 PTPN1 SNPs in this same block were associated with insulin sensitivity index (p=0.003) and fasting glucose (p<0.001), confirming the haplotype-level signal spans multiple ethnicities. Cheyssac et al. 2006⁶⁶ Cheyssac et al. 2006
Cheyssac C et al. Analysis of common PTPN1 gene variants in type 2 diabetes, obesity and associated phenotypes in the French population. BMC Med Genet. 2006 identified rs941798 — the most replicated variant in this block — as showing associations with fasting insulin, HOMA-B, and lipid levels in a French cohort, with rs6020611 in the same high-LD region.

Evidence level is moderate: the cholesterol finding for rs6020611 specifically derives from a single modest-sized cohort (n=382) and is specific to lean men; it awaits replication at scale. The broader insulin/T2D signal from this LD block is strong and replicated, but most of that literature focuses on rs941798, rs1885177, and the 1484insG variant rather than rs6020611 directly.

Practical Actions

Carrying the A allele — particularly in the AA genotype — does not guarantee elevated cholesterol or insulin resistance, but it tags a haplotype that chronically suppresses insulin signaling. The most actionable implication is monitoring: lean individuals carrying A alleles should track fasting LDL, fasting insulin, and HOMA-IR periodically, as PTP1B-driven risk may be present even at normal body weight. Reducing saturated fat intake lowers the hepatic substrate for LDL production; replacing refined carbohydrates with low-glycemic sources reduces demand on a partially blunted insulin signal. Resistance training and visceral fat reduction independently downregulate PTP1B expression in skeletal muscle, partially offsetting the genetic predisposition.

Interactions

rs6020611 is in high LD with rs941798, the anchor variant of the PTPN1 risk haplotype. Individuals who carry the A allele at rs6020611 are likely to co-carry the risk allele at rs941798 and the 1484insG insertion. If both rs6020611 and rs941798 data are available, the combination provides stronger haplotype resolution than either alone. The PTPN1 locus also interacts biologically with INSR (insulin receptor), IRS1, and PIK3R1 (PI3K regulatory subunit) — downstream components of the insulin signaling cascade whose variants compound PTP1B-driven impairment.